No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 249.0x · 10Y median 289.4x · 43rd percentile · as of Oct 6, 2026
Annual revenue · last 0 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:12:57.804Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Lunai Bioworks Inc. (LNAI) stock was $1.15 as of Oct 6, 2026, 11:10 AM EDT, up 0.88% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -88.8%
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems.
Biotechnology · Los Angeles, CA
Next Earnings Date
Oct 9, 2026
3 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.80
vs Estimate
N/A
Revenue
$20942.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LNAI | $5.21M | $1.15 | +0.88% | -88.84% | N/A | N/A | N/A |
| 2LIMN | $5.23M | $3.89 | -2.51% | -95.32% | N/A | N/A | vs LNAI |
| 3GELS | $5.17M | $0.56 | +3.63% | -57.02% | N/A | N/A | vs LNAI |
| 4INBS | $5.26M | $1.58 | -5.09% | -85.59% | -80.26% | N/A | vs LNAI |
| 5IMNN | $5.11M | $1.22 | -1.95% | -76.74% | -63.83% | -55.17% | vs LNAI |
| 6ALZN | $5.36M | $1.41 | -0.11% | -44.11% | -79.14% | N/A | vs LNAI |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.15
High
N/A
